These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1018 related articles for article (PubMed ID: 28556970)

  • 1. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
    Yin W; Song Y; Liu Q; Wu Y; He R
    Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemerin partly mediates tumor-inhibitory effect of all-trans retinoic acid via CMKLR1-dependent natural killer cell recruitment.
    Song Y; Yin W; Dan Y; Sheng J; Zeng Y; He R
    Immunology; 2019 Jul; 157(3):248-256. PubMed ID: 31063220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity.
    Rossi M; Carboni S; Di Berardino-Besson W; Riva E; Santiago-Raber ML; Belnoue E; Derouazi M
    Front Immunol; 2021; 12():695056. PubMed ID: 34276686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
    Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
    Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All-trans retinoic acid inhibits type 1 diabetes by T regulatory (Treg)-dependent suppression of interferon-gamma-producing T-cells without affecting Th17 cells.
    Van YH; Lee WH; Ortiz S; Lee MH; Qin HJ; Liu CP
    Diabetes; 2009 Jan; 58(1):146-55. PubMed ID: 18984738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of effector CD8+ T-cell function by tumour-associated B7-H3 and modulation of its counter-receptor triggering receptor expressed on myeloid cell-like transcript 2 at tumour sites.
    Kobori H; Hashiguchi M; Piao J; Kato M; Ritprajak P; Azuma M
    Immunology; 2010 Jul; 130(3):363-73. PubMed ID: 20141543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroartemisinin inhibits melanoma by regulating CTL/Treg anti-tumor immunity and STAT3-mediated apoptosis via IL-10 dependent manner.
    Yu R; Jin L; Li F; Fujimoto M; Wei Q; Lin Z; Ren X; Jin Q; Li H; Meng F; Jin G
    J Dermatol Sci; 2020 Sep; 99(3):193-202. PubMed ID: 32859456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.
    Tang Q; Jiang J; Liu J
    Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells.
    Roberts DJ; Franklin NA; Kingeter LM; Yagita H; Tutt AL; Glennie MJ; Bullock TN
    J Immunother; 2010 Oct; 33(8):769-79. PubMed ID: 20842060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells.
    Kato Y; Yoshino I; Egusa C; Maeda T; Pili R; Tsuboi R
    J Dermatol Sci; 2014 Aug; 75(2):140-7. PubMed ID: 24866536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma.
    Bertrand F; Rochotte J; Colacios C; Montfort A; Tilkin-Mariamé AF; Touriol C; Rochaix P; Lajoie-Mazenc I; Andrieu-Abadie N; Levade T; Benoist H; Ségui B
    Cancer Res; 2015 Jul; 75(13):2619-28. PubMed ID: 25977337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
    Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
    J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of murine tumour growth through CD8
    Kogo H; Shimizu M; Negishi Y; Uchida E; Takahashi H
    Immunology; 2017 Jul; 151(3):324-339. PubMed ID: 28294313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model.
    Ishii-Osai Y; Yamashita T; Tamura Y; Sato N; Ito A; Honda H; Wakamatsu K; Ito S; Nakayama E; Okura M; Jimbow K
    J Dermatol Sci; 2012 Jul; 67(1):51-60. PubMed ID: 22622238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.
    Thounaojam MC; Dudimah DF; Pellom ST; Uzhachenko RV; Carbone DP; Dikov MM; Shanker A
    Oncotarget; 2015 Oct; 6(32):32439-55. PubMed ID: 26431276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.